News

Sunny Pharmtech Inc. has been honored with the 12th Dun & Bradstreet Taiwan Elite SME Award, standing out among numerous competitors. This prestigious recognition highlights the company’s outstanding business performance and international competitiveness, once again affirming the important role Taiwanese SMEs play in the global market.

Dun & Bradstreet, a globally renowned provider of business data and analytics, hosts the annual Elite SME Award to recognize companies excelling in revenue growth, export performance, innovation, and financial stability. This year’s selection was made from over 1.5 million Taiwanese SMEs, with only the top 1% chosen as representatives. Sunny Pharmtech's outstanding performance not only highlights its strong R&D capabilities and business strategy but also signifies the continued growth potential of Taiwan's pharmaceutical industry on the global stage.

Since its establishment, Sunny Pharmtech has focused on the research, development, and manufacturing of high-quality generic drugs. The company has actively pursued international regulatory certifications, with products already marketed in Southeast Asia, the Middle East, and Latin America. In facing the challenges of the post-pandemic era, Sunny Pharmtech continues to invest in smart manufacturing and digital transformation, strengthening its industrial resilience and global footprint.

This award not only symbolizes the company’s strength but also highlights Sunny Pharmtech’s outstanding performance in sustainable development, R&D innovation, and market expansion. Looking forward, the company is committed to setting even higher standards and driving the advancement of Taiwan’s pharmaceutical industry.